- AU$33.90m
- -AU$33.93m
- AU$14.60m
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 08:59 PM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 08:29 PM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 08:02 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Immutep - To Focus Efti Development On Hnscc With Cps < 1 And Neoadjuvant Sts
Australia's Immutep falls to near 3-week low as 2026 loss widens
Brief: Immutep Says No Dividends Paid Or Declared During Current FY
Brief: Immutep Receives NASDAQ Notice Of Minimum Bid Price Non-Compliance
Australia's Immutep extends gain on FDA orphan drug status for cancer drug
Brief: Immutep Ltd Says FDA Granted Orphan Drug Designation For Eftilagimod alfa In Soft Tissue Sarcoma
Brief: Immutep Discontinues Phase III Tacti-004 Study In Non-Small Cell Lung Cancer
Brief: Dr Reddy's Says IDMC Recommends Discontinuation Of TACTI-004 Phase III Trial After Interim Futility Analysis
Immutep craters 93% to record low after ceasing Phase III study of lung cancer drug
Australia's Immutep hits record low on ceasing Phase III study of lung cancer treatment
Brief: Immutep Says TACTI-004 To Be Discontinued Following Futility Analysis